Epoxyeicosatrienoic acids function as selective, endogenous antagonists of native thromboxane receptors: Identification of a novel mechanism of vasodilation

Journal of Pharmacology and Experimental Therapeutics

Volumn 328, Issue 1, 2009, Pages 231-239

  Behm, David J ^a   Ogbonna, Andrea ^a   Wu, Charlene ^a   Burns Kurtis, Cynthia L ^a   Douglas, Stephen A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 FLUORO 9,15 DIHYDROXY 15 (2 INDANYL) 16,17,18,19,20 PENTANORPROSTA 5,13 DIENOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 3 BENZYL 5 (6 CARBOXYHEXYL) 1 (2 CYCLOHEXYL 2 HYDROXYETHYLAMINO)HYDANTOIN; 5 (6 CARBOXYHEXYL) 1 (3 CYCLOHEXYL 3 HYDROXYPROPYL)HYDANTOIN; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ARACHIDONIC ACID; BUTAPROST; CALCIUM ACTIVATED POTASSIUM CHANNEL; CAY 10441; DIHYDROXYICOSATRIENOIC ACID; EPOXYICOSATRIENOIC ACID; FLUPROSTENOL; G PROTEIN COUPLED RECEPTOR; ILOPROST; LEUKOTRIENE B4 RECEPTOR; LEUKOTRIENE C4 RECEPTOR; LEUKOTRIENE D4 RECEPTOR; LEUKOTRIENE RECEPTOR; PHENYLEPHRINE; PROSTANOID RECEPTOR; RECOMBINANT RECEPTOR; SC 51322; SULPROSTONE; THROMBOXANE RECEPTOR; THROMBOXANE RECEPTOR BLOCKING AGENT; THROMBOXANE RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 4; 14,15 EPOXY 5,8,11 EICOSATRIENOIC ACID; 14,15-EPOXY-5,8,11-EICOSATRIENOIC ACID; ARACHIDONIC ACID DERIVATIVE; DIHOMO GAMMA LINOLENIC ACID; DRUG DERIVATIVE; HYDROXYICOSATETRAENOIC ACID; TRPV4 PROTEIN, MOUSE; VANILLOID RECEPTOR;

ANIMAL TISSUE; ARTERY RESISTANCE; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; KNOCKOUT MOUSE; MESENTERIC ARTERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; VASODILATATION; WILD TYPE; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; GENETICS; GUINEA PIG; MALE; MOUSE MUTANT; PHYSIOLOGY; SPLANCHNIC BLOOD FLOW; SPRAGUE DAWLEY RAT; THORACIC AORTA; TRACHEA; VASCULAR RESISTANCE; VASOCONSTRICTION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; 8,11,14-EICOSATRIENOIC ACID; ANIMALS; AORTA, THORACIC; ARACHIDONIC ACIDS; GUINEA PIGS; HYDROXYEICOSATETRAENOIC ACIDS; MALE; MICE; MICE, KNOCKOUT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, THROMBOXANE; SPLANCHNIC CIRCULATION; TRACHEA; TRPV CATION CHANNELS; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATION;

EID: 59149084039     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.145102     Document Type: Article

References (40)

1. Abramovitz M, Adam M, Boie Y, Carrière M, Denis D, Godbout C, Lamontagne S, Rochette C, Sawyer N, Tremblay NM, et al. (2000) The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 1483:285-293.
2. Archer SL, Gragasin FS, Wu X, Wang S, McMurtry S, Kim DH, Platonov M, Koshal A, Hashimoto K, Campbell WB, et al. (2003) Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12- epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. Circulation 107: 769-776.
3. Campbell WB, Gebremedhin D, Pratt PF, and Harder DR (1996) Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78:415-423.
4. Capdevila J, Chacos N, Werringloer J, Prough RA, and Estabrook RW (1981) Liver microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid. Proc Natl Acad Sci U S A 78:5362-5366.
5. Capdevila JH, Karara A, Waxman DJ, Martin MV, Falck JR, and Guenguerich FP (1990) Cytochrome P-450 enzyme-specific control of the regio- and enantiofacial selectivity of the microsomal arachidonic acid epoxygenase. J Biol Chem 265: 10865-10871.
6. Carroll MA, Balazy M, Margiotta P, Falck JR, and McGiff JC (1993) Renal vasodilator activity of 5,6-epoxyeicosatrienoic acid depends upon conversion by cyclo-oxygenase and release of prostaglandins. J Biol Chem 268:12260-12266.
7. Douglas SA, Behm DJ, Aiyar NV, Naselsky D, Disa J, Brooks DP, Ohlstein EH, Gleason JG, Sarau HM, Foley JJ, et al. (2005) Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375. Br J Pharmacol 145:620-635.
8. Earley S, Heppner TJ, Nelson MT, and Brayden JE. TRPV4 forms a novel Ca2 + signaling complex with ryanodine receptors and BKCa channels (2005) Circ Res 97:1270-1279.
9. Fleming EF, Athirakul K, Oliverio MI, Key M, Goulet J, Koller BH, and Coffman TM (1998) Urinary concentrating function in mice lacking EP3 receptors for prostaglandin E2. Am J Physiol 275:F955-F961.
10. Fornage M, Lee CR, Doris PA, Bray MS, Heiss G, Zeldin DC, and Boerwinkle E (2005) The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum Mol Genet 14:2829-2837.
11. Homma T, Zhang JY, Shimizu T, Prakash C, Blair IA, and Harris RC (1993) Cyclooxygenase-derived metabolites of 8,9-epoxyeicosatrienoic acid are potent mitogens for cultured rat glomerular mesangial cells. Biochem Biophys Res Commun 191:282-288.
12. Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, and Hammock BD (2005) An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46:975-981.
13. Inceoglu B, Jinks SL, Schmelzer KR, Waite T, Kim IH, and Hammock BD (2006) Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci 79:2311-2319.
14. Kozak W, Aronoff DM, Boutaud O, and Kozak A (2003) 11,12- Epoxyeicosatrienoic acid attenuates synthesis of prostaglandin E2 in rat monocytes stimulated with lipopolysaccharide. Exp Biol Med (Maywood). 228:786-794.
15. Larsen BT, Campbell WB, and Gutterman DD (2007) Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system. Trends Pharmacol Sci 28:32-38.
16. Larsen BT, Miura H, Hatoum OA, Campbell WB, Hammock BD, Zeldin DC, Falck JR, and Gutterman DD (2006) Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol 290:H491-H499.
17. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ, Heiss G, and Zeldin DC (2006) Genetic variation in soluble epoxide hydrolase (EPHX2) and risk ofcoronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 15:1640-1649.
18. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, and Zeldin DC (2007) CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet Genomics 17:349-358.
19. Li PL and Campbell WB (1997) Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res 80:877-884.
20. Massot O, Rousselle JC, Fillion MP, Grimaldi B, Cloëz-Tayarani I, Fugelli A, Prud-homme N, Seguin L, Rousseau B, Plantefol M, et al. (1996) 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors. Mol Pharmacol 50:752-762.
21. + channel. J Biol Chem 279:36746-36752.
22. Monti J, Fischer J, Paskas S, Heinig M, Schulz H, Gösele C, Heuser A, Fischer R, Schmidt C, Schirdewan A, et al. (2008) Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet 40:529-537.
23. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, and Liao JK (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eico-sanoids. Science 285:1276-1279.
24. Node K, Ruan XL, Dai J, Yang SX, Graham L, Zeldin DC, and Liao JK (2001) Activation of Gas mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem 276:15983-15989.
25. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, and Barsh GS (1997) Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278:135-138.
26. Oltman CL, Weintraub NL, VanRollins M, and Dellsperger KC (1998) Epoxyeicosa-trienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ Res 83:932-939.
27. Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, Gabel S, Gooch R, Foley J, Newman J, Mao L, et al. (2004) Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res 95:506-514.
28. Seubert JM, Sinal CJ, Graves J, DeGraff LM, Bradbury JA, Lee CR, Goralski K, Carey MA, Luria A, Newman JW, et al. (2006) Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 99:442-450.
29. Snyder GD, Krishna UM, Falck JR, and Spector AA (2002) Evidence for a membrane site of action for 14,15-EET on expression of aromatase in vascular smooth muscle. Am J Physiol Heart Circ Physiol 283:H1936 -H1942.
30. Spector AA and Norris AW (2007) Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 292:C996 -C1012.
31. Thorneloe KS, Sulpizio AC, Lin Z, Figueroa DJ, Clouse AK, McCafferty GP, Chen-drimada TP, Lashinger ES, Gordon E, Evans L, et al. (2008) N-((1S)-1-{[4-((2S)-2-{[(2,4-Dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl) -1-piperazinyl]car- bonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: part I. J Pharmacol Exp Ther 326:432-442.
32. Vriens J, Owsianik G, Fisslthaler B, Suzuki M, Janssens A, Voets T, Morisseau C, Hammock BD, Fleming I, Busse R, et al. (2005) Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ Res 97:908-915.
33. Weintraub NL, Fang X, Kaduce TL, VanRollins M, Chatterjee P, and Spector AA (1997) Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. Circ Res 81:258-267.
34. Wilson RJ, Giblin GMP, Roomans S, Rhodes SA, Cartwright KA, Shield VJ, Brown J, Wise A, Chowdhury J, Pritchard S, et al. (2006) GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl] acetyl} benzene sul- phonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br J Pharmacol 148:326-339.
35. Wong PY, Lai PS, and Falck JR (2000) Mechanism and signal transduction of 14 (R), 15 (S)-epoxyeicosatrienoic acid (14,15-EET) binding in guinea pig monocytes. Prostaglandins Other Lipid Mediat 62:321-333.
36. Yang W, Tuniki VR, Anjaiah S, Falck JR, Hillard CJ, and Campbell WB (2008) Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20-125I-14,15-epoxyeicosa-8(Z)-enoic acid. J Pharmacol Exp Ther 324:1019-1027.
37. Yasar U, Bennet AM, Eliasson E, Lundgren S, Wiman B, De Faire U, and Rane A (2003) Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 13:715-720.
38. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, et al. (2000) Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 87:992-998.
39. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, and Imig JD (2004) Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 15:1244-1253.
40. Zou AP, Fleming JT, Falck JR, Jacobs ER, Gebremedhin D, Harder DR, and Roman RJ (1996) Stereospecific effects ofepoxyeicosatrienoic acids on renal vascular tone and K(+ )-channel activity. Am J Physiol 270:F822-F832.